SAB Biotherapeutics Inc

Research SAB Biotherapeutics Inc (SABS) on Bullrun: market cap USD 298.21M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerSABS
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 298.21M
• Financial periodFY2025
• Revenue growth-100.0%
• Net incomeUSD 13.27M
• Free cash flow-USD 45.71M

Valuation Snapshot

latest market cap is USD 298.21M.

About SAB Biotherapeutics Inc

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.

Frequently asked questions

What is SAB Biotherapeutics Inc's market cap?

SAB Biotherapeutics Inc's market capitalization is USD 298.21M.

What does SAB Biotherapeutics Inc do?

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States.